Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Compare

2,151 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARCT Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Arcturus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARCT Stock 12 Month Forecast

Average Price Target

$16.74

▲(152.49% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $16.74 with a high forecast of $25.00 and a low forecast of $7.91. The average price target represents a 152.49% change from the last price of $6.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","26":"$26","10.25":"$10.25","15.5":"$15.5","20.75":"$20.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10.25,15.5,20.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,9.63076923076923,10.911538461538461,12.192307692307692,13.473076923076922,14.753846153846153,16.034615384615385,17.315384615384616,18.596153846153847,19.876923076923077,21.157692307692308,22.43846153846154,23.71923076923077,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,8.995384615384616,9.64076923076923,10.286153846153846,10.93153846153846,11.576923076923077,12.222307692307691,12.867692307692307,13.513076923076923,14.158461538461538,14.803846153846152,15.449230769230768,16.094615384615384,{"y":16.74,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,8.316153846153846,8.282307692307691,8.248461538461537,8.214615384615385,8.180769230769231,8.146923076923077,8.113076923076923,8.079230769230769,8.045384615384615,8.011538461538462,7.977692307692307,7.943846153846154,{"y":7.91,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$16.74

Lowest Price Target$7.91

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

Hold

35.75%

Upside

Reiterated

03/05/26

Arcturus Therapeutics (ARCT) Gets a Hold from H.C. Wainwright

Whitney Ijem

Canaccord Genuity

$66→$21

Buy

216.74%

Upside

Reiterated

03/05/26

Arcturus Therapeutics price target lowered to $21 from $66 at CanaccordArcturus Therapeutics price target lowered to $21 from $66 at Canaccord

Myles Minter

William Blair

$7.91

Buy

19.31%

Upside

Reiterated

03/04/26

Analysts Offer Insights on Healthcare Companies: Rigel (NASDAQ: RIGL), Arcturus Therapeutics (NASDAQ: ARCT) and Intellia Therapeutics (NASDAQ: NTLA)

Seamus Fernandez

Guggenheim

―

Hold

―

Reiterated

03/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), Arcturus Therapeutics (NASDAQ: ARCT) and ImmunityBio (NASDAQ: IBRX)

Yasmeen Rahimi

Piper Sandler

$72→$25

Buy

277.07%

Upside

Reiterated

03/04/26

Arcturus Therapeutics (ARCT) Receives a Buy from Piper Sandler

Yanan Zhu

Wells Fargo

$20

Buy

201.66%

Upside

Reiterated

03/04/26

Wells Fargo Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)

Adam Walsh

Roth MKM

$20

Buy

201.66%

Upside

Reiterated

03/04/26

Analysts Are Bullish on Top Healthcare Stocks: 908 Devices (MASS), Arcturus Therapeutics (ARCT)

Yigal Nochomovitz

Citi

$7→$8

Hold

20.66%

Upside

Assigned

03/04/26

Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price

Thomas Shrader

BTIG

$23

Buy

246.91%

Upside

Reiterated

03/03/26

Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating

Lili (Aurélie) Nsongo

Leerink Partners

$54→$17

Buy

156.41%

Upside

Reiterated

10/23/25

Leerink Partners Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

Greg Harrison

Scotiabank

$32→$35

Buy

427.90%

Upside

Reiterated

07/02/25

Scotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

07/01/25

Cantor Fitzgerald Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

Ed Arce

Westpark Capital

$60

Buy

804.98%

Upside

Reiterated

04/11/25

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

Hold

35.75%

Upside

Reiterated

03/05/26

Arcturus Therapeutics (ARCT) Gets a Hold from H.C. Wainwright

Whitney Ijem

Canaccord Genuity

$66→$21

Buy

216.74%

Upside

Reiterated

03/05/26

Arcturus Therapeutics price target lowered to $21 from $66 at CanaccordArcturus Therapeutics price target lowered to $21 from $66 at Canaccord

Myles Minter

William Blair

$7.91

Buy

19.31%

Upside

Reiterated

03/04/26

Analysts Offer Insights on Healthcare Companies: Rigel (NASDAQ: RIGL), Arcturus Therapeutics (NASDAQ: ARCT) and Intellia Therapeutics (NASDAQ: NTLA)

Seamus Fernandez

Guggenheim

―

Hold

―

Reiterated

03/04/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), Arcturus Therapeutics (NASDAQ: ARCT) and ImmunityBio (NASDAQ: IBRX)

Yasmeen Rahimi

Piper Sandler

$72→$25

Buy

277.07%

Upside

Reiterated

03/04/26

Arcturus Therapeutics (ARCT) Receives a Buy from Piper Sandler

Yanan Zhu

Wells Fargo

$20

Buy

201.66%

Upside

Reiterated

03/04/26

Wells Fargo Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)

Adam Walsh

Roth MKM

$20

Buy

201.66%

Upside

Reiterated

03/04/26

Analysts Are Bullish on Top Healthcare Stocks: 908 Devices (MASS), Arcturus Therapeutics (ARCT)

Yigal Nochomovitz

Citi

$7→$8

Hold

20.66%

Upside

Assigned

03/04/26

Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price

Thomas Shrader

BTIG

$23

Buy

246.91%

Upside

Reiterated

03/03/26

Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating

Lili (Aurélie) Nsongo

Leerink Partners

$54→$17

Buy

156.41%

Upside

Reiterated

10/23/25

Leerink Partners Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

Greg Harrison

Scotiabank

$32→$35

Buy

427.90%

Upside

Reiterated

07/02/25

Scotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

07/01/25

Cantor Fitzgerald Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

Ed Arce

Westpark Capital

$60

Buy

804.98%

Upside

Reiterated

04/11/25

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcturus Therapeutics

3 Months

xxx

Success Rate

4/12 ratings generated profit

Average Return

-0.50%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -0.50% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

1/17 ratings generated profit

Average Return

-4.82%

a rating ―

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -4.82% per trade.

2 Years

xxx

Success Rate

1/17 ratings generated profit

Average Return

-48.78%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 5.88% of your transactions generating a profit, with an average return of -48.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARCT Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARCT has received 11 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ARCT average Analyst price target in the past 3 months is 16.74.

Each month's total comprises the sum of three months' worth of ratings.

ARCT Financial Forecast

ARCT Earnings Forecast

Next quarter’s earnings estimate for ARCT is -$1.00 with a range of -$1.38 to -$0.07. The previous quarter’s EPS was -$1.03. ARCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ARCT has Performed in-line its overall industry.

ARCT Sales Forecast

Next quarter’s sales forecast for ARCT is $5.90M with a range of $0.00 to $10.00M. The previous quarter’s sales results were $3.08M. ARCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ARCT has Performed in-line its overall industry.

ARCT Stock Forecast FAQ

What is ARCT’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is 16.74.

What is ARCT’s upside potential, based on the analysts’ average price target?

Arcturus Therapeutics has 152.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARCT a Buy, Sell or Hold?

Arcturus Therapeutics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Arcturus Therapeutics’s price target?

The average price target for Arcturus Therapeutics is 16.74. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $7.91. The average price target represents 152.49% Increase from the current price of $6.63.

What do analysts say about Arcturus Therapeutics?

Arcturus Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ARCT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

ARCT Analyst Ratings

ARCT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcturus Therapeutics

ARCT Analyst Recommendation Trends

ARCT Financial Forecast

ARCT Earnings Forecast

ARCT Sales Forecast

ARCT Stock Forecast FAQ

Detailed List of Analyst Forecasts